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3. Progress Report  
The goal of our research program is to evaluate--at both the cellular and 
enzymatic levels-•novel compounds of our own design which represent analogs of 
catecholamines and related compounds. Our compound are designed as either pro-
drugs, novel enzyme substrates, or suicide inactivators, and they fall into three 
general classes--ketone-generating, heteroatom-containing, and olefin-containing 
neurotransmitter analogs. 
The following paragraphs summarize our progress during the first year of 
this project. 
Heteroatom-containing analogs; In previous work, Phenyl-2-aminoethylsulfide (PAES) 
has been designed, synthesized and characterized in our laboratories as a novel 
synthetic substrate for dopamine-(3-hydroxylase (DBH). We have discovered the 
conversion of PAES by DBH to the corresponding sulfoxide, phenyl-2-aminoethyl-
sulfoxide (PAESO) and have investigated the kinetics and mechanism of this 
oxygenation reaction. These findings represented the first demonstration of 
oxygenation of a hetroatom by a specific hydroxylase such as DBH. One of the 
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more striking aspects of these findings is the fact that DBH oxygenates PAES 
more rapidly than the corresponding aliphatic carbon analog. In addition, 
we have established that the stereochemistry of the sulfoxidation reaction is 
fully consistent of that of other DBH reactions. 
This work has now been extended in two directions. In the first place, we 
have just recently discovered that selenium analogs are also excellent substrates 
for DBH, and it is therefore likely that other heteroatom will also be oxygenated 
by this enzyme. Thus, these findings open up many new approaches for the design 
of heteroatom-containing DBH substrates, and for the evaluation of these compounds 
at both the enzymatic and cellular levels. We are now completing characteriza-
tions of the selenium-oxidizing activity of DBH, and a manuscript describing these 
results will be submitted for publication shortly. 
The second direction in which we have extended our studies with PAES is the 
in vivo characterization of the effects of this compound in anesthetized dog. We 
have found that PAES possesses very little, if any, direct adrenerigic agonist 
activity, but exhibits indirect sympathomimetic activity at relatively high doses 
(4 mg/kg). This assertion that PAES is a new indirect synpathometic is supported 
by our findings that pre-treatment with cocaine completely abolishes its sympatho-
metic activity, and that its effects are diminished in consecutive stimuli. 
Additionally, we have found that PAES infusion almost completely blocks the reflex 
tachycardia elicited by hydralazine, a direct vasodilator. In contrast, the pro-
duct of DBH oxygenation of PAES, PAESO, has been found to possess neither direct 
or indirect sympathometic activity. If PAES is being converted to PAESO by DBH 
in the adrenergic nerve terminal, thus competing with DBH oxygenation of dopamine 
to norepinephrine, then the inactivity of PAESO could have important clinical 
implications, since it would result in PAES being converted into a "false trans-
mitter". Thus, the exciting possibility arises that through the use of PAES, 
norepinephrine stores in peripheral adrenergic structures could be lowered in a 
controlled manner. Further experiments are in progress in order to evaluate the 
clinical implications of these findings, but we are most encouraged and excited 
by the results in hand to date. 
Olefinic Substrate Analogs: The results which we have obtained with this class 
of compounds during this past year have been very exciting to us. In the first 
place, we have now definitely established that our prototypic olefinic substrate, 
FAME, is both an excellent substrate for DBH and is, indeed, a suicide inactivator. 
A body of experimental evidence is now in hand to clearly support this conclusion. 
In the first place, after an extensive and difficult series of experiments, we have 
developed a protocol to identify the product of the oxytenation of PAME, and to 
compare its structure with the corresponding synthetic diol which we have succeeded 
in preparing and chacterizing. These experiments were made especially difficult 
by the fact that the epoxide product of PANE is expected to be highly reactive and 
unstable, due to its benzylic structure. We have thus unequivically established 
that DBH is indeed capable of carrying the oxygenation of olefins, this once again 
representing a totally new activity for this enzyme. Inactivation studies with 
PANE have now established that it exhibits all of the characteristics expected for 
a suicide inactivator. Inactivation is irreversible, exhibits time and concentra-
tion dependencies, and is protected against by substrates. The inactivation 
reaction exhibits first-order kinetics and the data give a linear double reciprocal 
plot. DBH inactivitated by PANE is not reactivated upon extensive dialysis nor 
upon extended incubation in the presence of nucleophiles. Furthermore, the stoi-
chiometry for PANE oxygenation is precisly that expected for an oxygenase reaction. 
We are now just completing experiments with tritiated PAME, which has been prepared 
by the low pressure tritiation procedure described in our original proposal. 
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With this extensive body of experimental evidence now in hand, we will now 
proceed to the evaluation of the in-vivo effects of PAME and to the design of 
olefinic substrates of refined structure. Because of its simple chemical 
structure, there is no doubt in our minds that PANE will be readily taken up 
presynaptically, and thus we are especially interested in observing the effects 
of this compound in our bioassays. These experiments will be carried out during 
the second year of this project. 
Studies With Other Substrates Analogs: As described in our recent BBRC paper 
(ref. 1 above), it is our contention that the ketonization activity which we 
have demonstrated for DBH is relavent to the bioactivation of norpseudoephedrine 
and related compounds which contain the S-alcohol functionality at the benzylic 
position. Based on a large body of experimental evidence in the literature, we 
have no doubt that such compounds should be taken up and have access to DBH 
within synaptic vesicles. We are currently exploring the approach of producing 
pro-pro-drugs of this class through the resolution of dihydroxyphenyserines to 
obtain the diastereomer which will generate the S-ol after enzymatic decarbox-
glation, and thus will eventually generate the corresponding ketone after DBH 
ketonization. Experiments along these lines will be carried out during the 
coming year of this project. 
Finally, we have initiated the syntheses of second-generation substrate 
analogs from our three basic classes. For example, the PAES analog containing an 
a -methyl substituent is being prepared, since this analog will be much less 
susceptible to metabolism by MAO. Similarly, ring -oxygenated analogs which will 
have altered susceptibility to COMT are being prepared. It is our intention to 
examine the effects of such structural modifications on the activities of our 
compounds, and on the levels of naturally occurring catecholamines after 
administration of these compounds. 
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